Hypothesis

Age‑dependent enrichment of phosphatidylethanolamine (PE) in the endoplasmic reticulum (ER) lumen promotes a tighter BCL‑2/Beclin‑1 complex, thereby suppressing autophagy and fueling inflammasome‑driven inflammation. Restoring ER PE homeostasis disrupts this interaction independent of canonical post‑translational modifications, re‑activating autophagy and breaking the autophagy‑inflammasome vicious cycle.

Mechanistic Rationale

• BCL‑2’s ability to inhibit autophagy is restricted to its ER‑localized pool; mitochondrial BCL‑2 does not affect Beclin‑1 unless it binds AMBRA1【1】. This specificity suggests that ER‑resident lipids or protein partners modulate BCL‑2’s conformation or accessibility to Beclin‑1’s BH3 domain.
• PE is a cone‑shaped phospholipid that promotes negative curvature and can alter the packing of transmembrane helices. Increased ER PE, reported in aged tissues due to altered phosphatidylserine decarboxylase activity, could favor a microenvironment where BCL‑2’s transmembrane domain adopts a conformation that enhances its cytosolic groove’s affinity for Beclin‑1.
• Supporting this, lipid‑dependent regulation of Bcl‑2 family members has been observed at the mitochondria (e.g., cardiolipin binding to Bax), yet the analogous ER lipid code remains unexplored【2】.
• If PE enrichment stabilizes the BCL‑2/Beclin‑1 complex, then reducing ER PE should mimic the effect of JNK1/ERK phosphorylation or TRAF6‑mediated ubiquitination that dissociates the pair【3】—but via a purely biophysical route.

Testable Predictions

1. Correlation: ER PE levels will be significantly higher in hepatocytes, fibroblasts, and macrophages from old (≥24 mo) mice compared with young (3 mo) counterparts.
2. Causality: Pharmacological or genetic reduction of ER PE (e.g., supplementation with ethanolamine kinase inhibitor or overexpression of phosphatidylethanolamine‑N‑methyltransferase) will decrease BCL‑2/Beclin‑1 co‑immunoprecipitation without altering total BCL‑2 or Beclin‑1 expression.
3. Functional Outcome: Reduced ER PE will increase LC3‑II/I ratio and p62 degradation, indicating enhanced autophagic flux, and concurrently lower NLRP3 inflammasome activation (reduced caspase‑1 cleavage and IL‑1β secretion) in aged cells.
4. In Vivo Rescue: Old mice treated with an ER‑targeted PE‑lowering agent will show improved autophagic markers in liver and kidney, diminished fibrosis, and extended median lifespan recapitulating the ~10‑12% gain seen with Beclin‑1 F121A mutation【4】.

Experimental Approach

• Lipid Quantification: Isolate ER microsomes from young and old mouse tissues; quantify PE, phosphatidylcholine, and phosphatidylserine by LC‑MS/MS.
• Interaction Assay: Perform co‑IP of BCL‑2 and Beclin‑1 from ER fractions ± PE‑modulating drugs (e.g., ethyl‑phosphocholine to inhibit PE synthesis). Include controls for BCL‑2/Bax binding to ensure specificity.
• Autophagy Flux: Treat primary cultured cells with bafilomycin A1 and measure LC3 turnover by Western blot; use mCherry‑GFP‑LC3 reporter for autophagosome‑lysosome fusion.
• Inflammasome Readout: Assay ASC speck formation and caspase‑1 activity after LPS/ATP stimulation.
• In Vivo Study: Administer an ER‑targeted PE‑lowering peptide conjugate to aged mice for 6 months; monitor survival, histology (Sirius Red for fibrosis), and autophagy markers.

Potential Outcomes and Interpretation

• If predictions hold: Elevated ER PE is a novel upstream regulator of the BCL‑2/Beclin‑1 axis; manipulating ER lipid composition offers a lipid‑centric strategy to reactivate autophagy in aging without directly inhibiting BCL‑2’s anti‑apoptotic function.
• If ER PE does not correlate with BCL‑2/Beclin‑1 binding, or PE reduction fails to alter autophagy/inflammasome readouts, the hypothesis is falsified, directing focus back to protein‑centric mechanisms (phosphorylation, ubiquitination) or other ER‑resident regulators.

This hypothesis links membrane lipidomics to a well‑established protein interaction hub, providing a clear, falsifiable framework that can be addressed with existing biochemical, cell‑biological, and aging‑model tools.